Among preterm infants born at 22 to 28 wks’ gestation with a protocol-defined patent ductus arteriosus, does expectant management compared with active treatment decrease the incidence of death or bronchopulmonary dysplasia? #HotTopicsNeo2025
📽️ Watch the video & read the full article: ja.ma/4abzdf0
A new study published @jama.com found that treating PDA in preterm infants with NSAIDs or acetaminophen at ≤21 days of age did not help with disease management. In fact, for every 18 infants treated with expectant management, one more infant survived. #HotTopicsNeo2025
https://bit.ly/44H1Vkr
An editorial from JAMA titled 'Reconsidering Oxygen at Birth for Preterm Infants Lessons From TORPIDO 30/60' by Alyssa R. Thomas, MD; Elizabeth E. Foglia, MD, MSCE. It discusses oxygen levels for newborns, referencing NETMOTION and FIO2 levels.
💬 Editorial: Recent data from the TORPIDO 30/60 #RCT demonstrate that the choice of moderate initial FIO2 is not a primary determinant of mortality.
@nemours.bsky.social #HotTopicsNeo2025
ja.ma/3XKYhlG
JAMA study: Initiating resuscitation of preterm newborns with higher oxygen (FiO2 0.6) doesn't reduce death/brain injury risk compared to lower (FiO2 0.3). 797 females, 672 males. 31 hospitals in 6 countries. No difference in risk between groups.
Among preterm newborns, initiating resuscitation with FIO2 of 0.6 vs 0.3 did not change risk of death or major brain injury at 36 weeks’ corrected age in a multinational RCT.
@nemours.bsky.social #HotTopicsNeo2025
ja.ma/3XLVFDV
JAMA Research Summary: Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants. Trial shows 80.9% expectant management vs 79.6% active treatment for death or bronchopulmonary dysplasia at 36 weeks.
📊 Research Summary: Expectant management among infants with patent ductus arteriosus did not lower the risk of death or BPD compared with active treatment, but more infants survived in the expectant management group.
@nemours.bsky.social #HotTopicsNeo2025
ja.ma/4rIftGd
💬 Editorial: Trial by Laughon et al supports the growing consensus against routine pharmacologic closure of PDA in extremely preterm infants & aligns with updated clinical guidelines favoring expectant management and observation.
@nemours.bsky.social #HotTopicsNeo2025
ja.ma/4oOtZcL
JAMA study on preterm infants (22-28 weeks) with patent ductus arteriosus. Compares expectant vs active treatment. No difference in death/dysplasia, but more infants survived with expectant management. 482 infants randomized.
RCT: Among preterm infants with PDA, expectant management vs pharmacologic closure showed no difference in the composite outcome of death or BPD at 36 weeks and a lower risk of mortality compared with pharmacologic treatment.
@nemours.bsky.social #HotTopicsNeo2025
ja.ma/4pVMTPA
Hello from Hot Topics! 👋 The Incubator Podcast team is here today, December 9th. You can find us at Booth 11 in the exhibitor hall. Stop by and say hello, we'd love to see you!
#HotTopicsNeo2025 #HotTopicsNeo
JAMA 'Research Letter' shows a bar graph of 'Trends in Vitamin K Administration Among Infants' from 2017-2024. The Y axis shows '% of Nonreceipt of vitamin K', rising from ~3% in 2017-2019 to ~5% in 2024.
Between 2017 and 2024, the percentage of newborns not receiving intramuscular vitamin K for prophylaxis nearly doubled, with refusal rates highest outside hospital births and among certain racial and ethnic groups. #HotTopicsNeo2025 ja.ma/48nSkBf
JAMA publication: 'Prediction of Bacteremia and Bacterial Meningitis Among Febrile Infants Aged 28 Days or Younger'. Key points include study findings on prediction rule sensitivity, specificity, and predictive values.
The updated PECARN rule reliably identified low-risk febrile infants, with no missed cases of bacterial meningitis, potentially reducing routine lumbar punctures. #HotTopicsNeo2025 ja.ma/48G0bZw
A JAMA article titled "Moving the Field Forward to Safely Do Less With Febrile Neonates" by Justin B. Searns, MD; Sean T. O'Leary, MD, MPH. Published online December 8, 2025. Article discusses newborns with suspected infections.
Editorial: In prospective analysis, the updated PECARN rule accurately stratified risk for invasive bacterial infections in full-term febrile neonates, identifying a sizable low-risk group for whom invasive testing may be unnecessary. #HotTopicsNeo2025 ja.ma/4pJBsdY
